New Lung Cancer Drug Launches for Targeted Treatment

The drug provides a new daily oral treatment option for adults with advanced lung cancer carrying specific genetic mutations.

Updated on Oct. 31, 2026 in Cancer

Graduated glass beakers containing clear liquid in a sterile, modern laboratory setting. — AstraZeneca has launched ZEGFROVY in the United States, a new targeted oral treatment for patients with advanced non-small cell lung cancer. AI Illustration. Upload story photo >

Live Poll

Do you trust that new targeted cancer therapies significantly improve survival outcomes for most patients?

AstraZeneca has launched ZEGFROVY in the United States as a new targeted treatment for adults with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The medication is intended for patients who have already progressed following platinum-based chemotherapy.

Why it matters

This drug provides a new therapeutic option for a subtype of lung cancer that has historically proven difficult to treat with standard targeted therapies. Its availability offers a potential alternative for patients whose disease has advanced beyond initial treatment.

In a clinical trial of 85 patients, the drug demonstrated an overall response rate of 46% with a median duration of response of 11.1 months. While preliminary, 72% of responding patients maintained their response for at least six months.

The players

AstraZeneca

A global pharmaceutical company that focuses on oncology, cardiovascular, and respiratory medicine.

FDA

The federal agency responsible for regulating the safety and efficacy of pharmaceuticals in the United States.

National Comprehensive Cancer Network

A non-profit alliance of cancer centers that establishes evidence-based clinical practice guidelines.

The details

ZEGFROVY is a daily oral treatment that targets EGFR exon 20 insertion mutations in lung cancer cells. The drug is administered at a 200-milligram dose taken with food to support its mechanism of inhibiting abnormal protein signaling. Because it received accelerated approval from the FDA, ongoing evidence collection is required to confirm its clinical impact.

October 31, 2026: The launch of ZEGFROVY in the United States was reported.

Health Landscape

The inclusion of this new therapy in the National Comprehensive Cancer Network clinical practice guidelines follows a broader movement toward molecularly targeted lung cancer treatments. This approach marks a shift away from broader chemotherapy regimens for patients with specific genetic markers.

Patients with advanced non-small cell lung cancer should talk with their oncologist about whether genetic testing for EGFR exon 20 insertion mutations has been performed. This medication is available through specialty pharmacy networks and requires careful monitoring for side effects like pneumonitis.

The takeaway

Targeted therapies continue to expand the precision-medicine options available for complex lung cancer cases. Discuss the possibility of mutation-specific testing with your physician to understand if emerging treatment pathways are appropriate for your specific diagnosis.